Delivery of foreign antigens by engineered outer membrane vesicle vaccines

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 7, 2010, Pages 3099-3104

  Chen, David J ^a   Osterrieder, Nikolaus ^b,c   Metzger, Stephan M ^b   Buckles, Elizabeth ^b   Doody, Anne M ^a   DeLisa, Matthew P ^a   Putnam, David ^a  

^a Cornell University   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Adjuvant; Protein subunit

Indexed keywords

ALUMINUM HYDROXIDE; CHIMERIC PROTEIN; GREEN FLUORESCENT PROTEIN; HEMOLYSIN; HYBRID PROTEIN; OUTER MEMBRANE PROTEIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN PURIFICATION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; GENE FUSION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN LOCALIZATION; ULTRACENTRIFUGATION;

ANIMALS; ANTIGENS; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GREEN FLUORESCENT PROTEINS; HEMOLYSIN PROTEINS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; PROTEIN ENGINEERING; TRANSPORT VESICLES; ULTRACENTRIFUGATION; VACCINES;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS; OAT MOSAIC VIRUS;

EID: 77649248408     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805532107     Document Type: Article

References (45)

1. O'Hagan DT, Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2:727-735.
2. Wu YM, et al. (2006) Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci USA 103:18243-18248.
3. Koser ML, et al. (2004) Rabies virus nucleoprotein as a carrier for foreign antigens. Proc Natl Acad Sci USA 101:9405-9410.
4. Singh M, Chakrapani A, O'Hagan D (2007) Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 6:797-808.
5. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457-460.
6. Lowell GH, et al. (1988) Proteosome-lipopeptide vaccines: Enhancement of immunogenicity for malaria CS peptides. Science 240:800-802.
7. Lowell GH, Smith LF, Seid RC, Zollinger WD (1988) Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J Exp Med 167: 658-663.
8. Felnerova D, Viret JF, Glück R, Moser C (2004) Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 15:518-529.
9. Copland MJ, Rades T, Davies NM, Baird MA (2005) Lipid based particulate formulations for the delivery of antigen. Immunol Cell Biol 83:97-105.
10. Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: Challenges and solutions. Nat Biotechnol 24:1377-1383.
11. Oster P, et al. (2005) MeNZB: A safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191-2196.
12. Feiring B, et al. (2006) Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 13:790-796.
13. Beveridge TJ (1999) Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol 181:4725-4733.
14. Kuehn MJ, Kesty NC (2005) Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev 19:2645-2655.
15. Claassen I, et al. (1996) Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14:1001-1008.
16. Arigita C, et al. (2004) Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines. Vaccine 22:629-642.
17. de Kleijn ED, et al. (2000) Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 18: 1456-1466.
18. Sandbu S, et al. (2007) Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol 14: 1062-1069.
19. Kesty NC, Kuehn MJ (2004) Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles. J Biol Chem 279: 2069-2076.
20. Kouokam JC, Wai SN (2006) Outer membrane vesicle-mediated export of a poreforming cytotoxin from Escherichia coli. Toxin Reviews 25:31-46.
21. Wai SN, et al. (2003) Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin. Cell 115:25-35.
22. Kim J-Y, et al. (2008) Engineered bacterial outer membrane vesicles with enhanced functionality. J Mol Biol 380:51-66.
23. Galen JE, et al. (2004) Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect Immun 72:7096-7106.
24. Westermark M, Oscarsson J, Mizunoe Y, Urbonaviciene J, Uhlin BE (2000) Silencing and activation of ClyA cytotoxin expression in Escherichia coli. J Bacteriol 182: 6347-6357.
25. Levine MM, et al., ed (2004) New Generation Vaccines (Marcel Dekker, Inc., New York), 3rd Ed.
26. Rappuoli R, Miller HI, Falkow S (2002) Medicine. The intangible value of vaccination. Science 297:937-939.
27. Schijns VEJC, Degen WGJ (2007) Vaccine immunopotentiators of the future. Clin Pharmacol Ther 82:750-755.
28. Gupta RK (1998) Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32: 155-172.
29. Eickhoff TC, Myers M (2002) Workshop summary. Aluminum in vaccines. Vaccine 20 (Suppl 3):S1-S4.
30. Alaniz RC, Deatherage BL, Lara JC, Cookson BT (2007) Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol 179:7692-7701.
31. Bauman SJ, Kuehn MJ (2006) Purification of outer membrane vesicles from Pseudomonas aeruginosa and their activation of an IL-8 response. Microbes Infect 8: 2400-2408.
32. del Castillo FJ, Moreno F, del Castillo I (2001) Secretion of the Escherichia coli K-12 SheA hemolysin is independent of its cytolytic activity. FEMS Microbiol Lett 204: 281-285.
33. Eifler N, et al. (2006) Cytotoxin ClyA from Escherichia coli assembles to a 13-meric pore independent of its redox-state. EMBO J 25:2652-2661.
34. Lavelle EC, Leavy O, Mills KHG (2006) Vaccine Adjuvants: Immunological and Clinical Principles, eds Hackett CJ, Harn DA (Humana Press, Totowa, NJ), pp 111-154.
35. Wai SN, et al. (2003) Characterization of dominantly negative mutant ClyA cytotoxin proteins in Escherichia coli. J Bacteriol 185:5491-5499.
36. Bachmann MF, et al. (1993) The influence of antigen organization on B cell responsiveness. Science 262:1448-1451.
37. Li M, et al. (2001) Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 166:6099-6103.
38. Steeghs L, et al. (1999) Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: Influence of adjuvants on the immune response. Infect Immun 67:4988-4993.
39. Kolling GL, Matthews KR (1999) Export of virulence genes and Shiga toxin by membrane vesicles of Escherichia coli O157:H7. Appl Environ Microbiol 65:1843-1848.
40. Bernadac A, Gavioli M, Lazzaroni JC, Raina S, Lloubès R (1998) Escherichia coli tol-pal mutants form outer membrane vesicles. J Bacteriol 180:4872-4878.
41. Cormack BP, Valdivia RH, Falkow S (1996) FACS-optimized mutants of the green fluorescent protein (GFP). Gene 173:33-38.
42. Rowe GE, Welch RA (1994) Assays of hemolytic toxins. Methods Enzymol 235:657-667.
43. Karkhanis YD, Zeltner JY, Jackson JJ, Carlo DJ (1978) A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. Anal Biochem 85:595-601.
44. Herlax V, de Alaniz MJT, Bakás L (2005) Role of lipopolysaccharide on the structure and function of alpha-hemolysin from Escherichia coli. Chem Phys Lipids 135:107-115.
45. Lee CH, Tsai CM (1999) Quantification of bacterial lipopolysaccharides by the purpald assay: Measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal Biochem 267:161-168.